Shernan Holtan, MD

Hematologic Oncology

Shernan Holtan, MD

Specializing In:

Blood and marrow transplantationCellular immunotherapyImmune-based disease

View full profile

Related Videos

New CAR T-Cell Therapy Shows Promise as ‘Magic Bullet’ for Patients with Relapsed/Refractory AML — Even After Transplant Video

New CAR T-Cell Therapy Shows Promise as ‘Magic Bullet’ for Patients with Relapsed/Refractory AML — Even After Transplant

A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., is evaluating a new chimeric antigen receptor (CAR) T-cell therapy that could dramatically transform the treatment of relapsed ...

Graft Versus Host Disease No Longer Poses High Risk to Transplant Patients Video

Graft Versus Host Disease No Longer Poses High Risk to Transplant Patients

Graft versus host disease (GVHD) used to present such a risk to transplant patients, an estimate 10-15% of patients would develop a fatal case of it.

Meet the Team: Shernan Holtan, MD Video

Meet the Team: Shernan Holtan, MD

The newest member of the cellular therapy research team and Chief of the Bone Marrow and Transplantation Service at Roswell Park Comprehensive Cancer Center is eager to continue advancing the field.